Idefirix 11 mg powder for concentrate for solution for infusion clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)
This study is testing a new medicine, Idefirix, for a rare kidney disease called Goodpasture disease. Researchers want to see if Idefirix, along with usual care, helps kidney function better than usual care alone over six months.
For: Anti-GBM antibody disease (Goodpasture disease)Spain · Czechia · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non-comparative registry and concurrent reference cohorts
This study looks at a new medicine called Idefirix for people with severe kidney disease waiting for a kidney transplant. It aims to see how well Idefirix helps them receive a transplant and if the new kidney works well for a year after the transplant.
For: End stage chronic kidney disease (CKD) patients who are highly sensitised and on the kidney transplant list awaiting a kidney transplantGermany · Sweden · Belgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of SRP-9001 in Association with Imlifidase in Subjects with Duchenne Muscular Dystrophy with Pre-existing Antibodies to rAAVrh74
This study is looking at a new gene therapy for Duchenne muscular dystrophy in males who already have certain antibodies. It's testing if the treatment is safe, how well people tolerate it, and if the therapy's active ingredient can be produced in their muscles.
For: Duchenne muscular dystrophy (DMD)Spain